Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD PharmaTimesEarly safety and efficacy signals support move into repeatdose phase 2a trialOphthalmologyRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) PharmaTimes Early safety and efficacy signals support move into repeatdose phase 2a trial Ophthalmology Read full story Post navigation Previous: Lilly, Gilead lead pharma’s M&A boomNext: BMS’ Sotyktu secures EC approval for psoriatic arthritis Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026